363 related articles for article (PubMed ID: 21098761)
1. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Bonilla L; Ben-Aharon I; Vidal L; Gafter-Gvili A; Leibovici L; Stemmer SM
J Natl Cancer Inst; 2010 Dec; 102(24):1845-54. PubMed ID: 21098761
[TBL] [Abstract][Full Text] [Related]
2. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
3. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials.
Petrelli F; Cabiddu M; Coinu A; Borgonovo K; Ghilardi M; Lonati V; Barni S
Breast Cancer Res Treat; 2015 Jun; 151(2):251-9. PubMed ID: 25917869
[TBL] [Abstract][Full Text] [Related]
5. Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.
Zhou W; Chen S; Xu F; Zeng X
World J Surg Oncol; 2018 Jul; 16(1):144. PubMed ID: 30007402
[TBL] [Abstract][Full Text] [Related]
6. Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis.
Lemos Duarte I; da Silveira Nogueira Lima JP; Passos Lima CS; Deeke Sasse A
Breast; 2012 Jun; 21(3):343-9. PubMed ID: 22425607
[TBL] [Abstract][Full Text] [Related]
7. Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis.
Goldvaser H; Majeed H; Ribnikar D; Šeruga B; Ocaña A; Cescon DW; Amir E
Breast Cancer Res Treat; 2018 Jun; 169(3):413-425. PubMed ID: 29423899
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
Qian X; Li Z; Ruan G; Tu C; Ding W
Breast Cancer Res Treat; 2020 Jan; 179(2):275-285. PubMed ID: 31606823
[TBL] [Abstract][Full Text] [Related]
9. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
10. Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.
Conte B; Bruzzone M; Lambertini M; Poggio F; Bighin C; Blondeaux E; De Laurentiis M; Valle E; Cognetti F; Nisticò C; De Placido S; Garrone O; Gamucci T; Montemurro F; Puglisi F; Cardinali B; Fregatti P; Miglietta L; Boccardo F; Ceppi M; Del Mastro L;
Eur J Cancer; 2020 Sep; 136():43-51. PubMed ID: 32634760
[TBL] [Abstract][Full Text] [Related]
11. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
[TBL] [Abstract][Full Text] [Related]
12. CDK4/6 Inhibitors in Combination With Hormone Therapy for HR
Deng Y; Ma G; Li W; Wang T; Zhao Y; Wu Q
Clin Breast Cancer; 2018 Oct; 18(5):e943-e953. PubMed ID: 29804650
[TBL] [Abstract][Full Text] [Related]
13. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
[TBL] [Abstract][Full Text] [Related]
14. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
15. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Harris LN; Ismaila N; McShane LM; Andre F; Collyar DE; Gonzalez-Angulo AM; Hammond EH; Kuderer NM; Liu MC; Mennel RG; Van Poznak C; Bast RC; Hayes DF;
J Clin Oncol; 2016 Apr; 34(10):1134-50. PubMed ID: 26858339
[TBL] [Abstract][Full Text] [Related]
16. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
18. Is òne cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms.
Fizazi K; Zelek L
Ann Oncol; 2000 Feb; 11(2):133-49. PubMed ID: 10761747
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL
J Natl Cancer Inst; 2005 Sep; 97(17):1262-71. PubMed ID: 16145047
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
